Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Marine drugs
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/40422784/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Isolation and Characterization of L-Asparaginase-Producing Bacteria from the Arabian-Persian Gulf Region: First Report on ASP-J1-4 as a Producer and Its Potential Application. Al-Harbi, Ghofran M Kotb, Essam Almiman, Abeer A Berekaa, Mahmoud M Alhamad, Salwa Alahmady, Nada F Aljafary, Meneerah A Alqazlan, Nadiyah M Alyami, Reem I Alqarni, Joud M Al-Suhaimi, Ebtesam Abdullah Asparaginase Humans Antineoplastic Agents Bacillus HCT116 Cells Indian Ocean Cell Line, Tumor Hydrogen-Ion Concentration Asparagine L-asparaginase (L-ASNase) functions as a chemotherapeutic enzyme with antitumor properties. It facilitates the degradation of L-asparagine (L-ASN), a vital amino acid required for the proliferation of tumor cells. In this study, we have isolated 177 L-ASNase-producing strains from the aquatic environment of the Arabian-Persian Gulf. The most potent isolate, ASP-J1-4, was an endophyte recovered from the seablite and was molecularly identified as (accession number PQ593941). The enzyme purified through DEAE-Sepharose displayed a molecular weight of 37 kDa based on the SDS-PAGE profile and lacked detectable L-glutaminase (L-GTNase) activity. Optimal enzyme activity was at 40 °C and pH 9.0, with stability at pH 7-9. The maximum stimulation effect was found in the presence of Fe, Mn, and Na ions, respectively. The enzyme demonstrated a of 35.71 U/mL and a of 0.15 mM. Interestingly, ASP-J1-4 L-ASNase showed a dose-dependent inhibition against human colon carcinoma (HCT-116) and cervical Henrietta Lacks (HeLa) cell lines, with IC values of 15.42 µg/mL and 12.13 µg/mL, respectively. These findings collectively suggest a biocompatible, efficient, and robust enzyme for potential applications in tumor therapy after validation of in vivo studies and clinical trials. This study introduces the first deep screening program for L-ASNase-producing bacteria harboring in the Arabian-Persian Gulf region. In addition, it launches and other species as new sources of L-ASNase.